Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

  • End date
    Jul 7, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 7 July 2022
systemic therapy
direct bilirubin
neutrophil count
chemotherapy regimen
cancer therapy
sezary syndrome
systemic steroids
adrenal insufficiency
mycosis fungoides and sezary syndrome
pet scans
metastatic tumor


The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

Condition Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis Fungoides
Treatment Gemcitabine, Pembrolizumab
Clinical Study IdentifierNCT04960618
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on7 July 2022


Yes No Not Sure

Inclusion Criteria

Confirmed mycosis fungoides/Sezary syndrome, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher
Age ≥ 18 years
ECOG Performance Score between 0-1
Receipt of at least one prior systemic therapy for MF/SS
Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment. See section 6.2 Subject Exclusion Criteria for guidelines regarding adjuvant and maintenance therapy for prior malignancy
Topical or systemic steroids (equivalent to ≤ 10 mg/day of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering
Prior therapy with gemcitabine allowed
Refer to Table 1 for laboratory inclusion criteria
The participant (or legally acceptable representative if applicable) provides written informed consent for the trial
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies
Not a woman of childbearing potential (WOCBP) as defined in Appendix C
A WOCBP who agrees to follow the contraceptive guidance in Appendix C
A male participant must agree to use a contraception as detailed in Appendix C of this
Table 1: Laboratory Parameters for Inclusion Criteria
protocol from screening and through 6 months after the last dose of
System : Laboratory Value
gemcitabine or 120 days after the last dose of pembrolizumab (whichever is
later) and refrain from donating sperm during this period
Hematological Absolute neutrophil count (ANC): ≥ 1500/μL Platelets: ≥ 100 000/μL
Hemoglobin: ≥ 9.0 g/dL or ≥ 5.6 mmol/L^a
Renal Creatinine OR Measured or calculated^b creatinine clearance (GFR can also be used in
place of creatinine or CrCl): ≤ 1.5 × ULN OR ≥ 30 mL/min for participant with creatinine
participants with liver metastases)
levels > 1.5 × institutional ULN
Hepatic Total bilirubin: ≤ 1.5 ×ULN OR direct bilirubin ≤ ULN for participants with total
bilirubin levels >1.5 × ULN AST (SGOT) and ALT (SGPT): ≤ 2.5 × ULN (≤ 5 × ULN for
Coagulation International normalized ratio (INR) OR prothrombin time (PT) Activated partial
ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST
thromboplastin time (aPTT): ≤ 1.5 × ULN unless participant is receiving anticoagulant
therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
(SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular
b: Creatinine clearance (CrCl) should be calculated per institutional standard
filtration rate; ULN=upper limit of normal
a: Criteria must be met without erythropoietin dependency and without packed red blood
cell (pRBC) transfusion within last 2 weeks
Note: This table includes eligibility-defining laboratory value requirements for treatment
laboratory value requirements should be adapted according to local regulations and
guidelines for the administration of specific chemotherapies

Exclusion Criteria

A WOCBP who has a positive urine pregnancy test within 72 hours prior to the first
Has an active infection requiring systemic therapy
dose of treatment (see Appendix C). If the urine test is positive or cannot be
confirmed as negative, a serum pregnancy test will be required
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g
CTLA-4, OX 40, CD137)
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug
Has a known additional malignancy that is progressing or has required active treatment
Has a known history of Human Immunodeficiency Virus (HIV) infection
within the past year. Participants with basal cell carcinoma of the skin, squamous
cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical
cancer in situ) that have undergone potentially curative therapy are not excluded
Has had an allogenic tissue/solid organ transplant
Is currently participating in or has participated in a study of an investigational
Has a known history of active TB (Bacillus Tuberculosis)
agent or has used an investigational device within 4 weeks prior to the first dose of
study intervention. A shorter timeframe down to 2 weeks may be acceptable if the
investigator feels that this is in the best interests of the patient
Has received prior systemic anti-cancer therapy including investigational agents
phototherapy or radiotherapy within 4 weeks prior to the first dose of study
intervention excluding topical steroids. A shorter timeframe down to 2 weeks may be
acceptable if the investigator feels that this is in the best interests of the
Participants must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease
Has received a live vaccine within 30 days prior to the first dose of study drug
Examples of live vaccines include, but are not limited to, the following: measles
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette- Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed
Has active autoimmune disease that has required systemic treatment in the past year
(i.e. with use of disease modifying agents, corticosteroids (exceeding 10 mg daily of
prednisone equivalent or immunosuppressive drugs). Replacement therapy (e.g
thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or
pituitary insufficiency, etc.) is not considered a form of systemic treatment
Has known active CNS lymphoma. Participants with previously treated CNS lymphoma may
participate provided they are radiologically stable, i.e. without evidence of
progression for at least 4 weeks by repeat imaging (note that the repeat imaging
should be performed during study screening), clinically stable and without requirement
of steroid treatment for at least 14 days prior to first dose of study intervention
Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy
(other than T-cell lymphoma) is permissible after discussion with the Principal
Has known active Hepatitis B (defined as Hepatitis B DNA detected by PCR) or known
active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
Patients with evidence of prior hepatitis B infection require prophylaxis with
entecavir or equivalent
Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease
Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator
Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial
Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 6 months
after the last dose of gemcitabine or 120 days after the last dose of pembrolizumab
(whichever is later). See Appendix C for details regarding contraception
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note